X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.fiercebiotech.com/biotech/novartis-asciminib-bests-pfizer-s-bosulif-phase-3-leukemia-trial
https://www.raps.org/news-and-articles/news-articles/2018/2/ema%E2%80%99s-chmp-recommends-five-new-medicines-for-appro?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails&_zs=VHOsL1&_zl=k7BK4
http://www.pharmatimes.com/news/first-line_use_of_pfizers_bosulif_cleared_in_the_us_1214830
http://www.pharmatimes.com/news/pfizer,_avillion_file_for_bosulif_expansion_1203702
http://www.fiercepharma.com/pharma/pfizer-s-ibrance-combo-faces-tough-review-at-nice-exec-worries
http://www.reuters.com/article/us-health-cancer-britain-idUSKBN12Y004
http://www.fiercepharma.com/pharma/nice-reverses-2013-decision-recommending-pfizer-s-bosulif
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-eng.php
http://twofourinsight.com/health-canadarequires-warning-gleevec-labeling-brand-generics/
http://www.fiercepharma.com/story/nhs-watchdog-takes-issue-pfizer-execs-new-role-foundation-trusts-board/2016-01-20
http://www.pharmatimes.com/Article/15-09-06/Twenty-three_therapies_axed_from_Cancer_Drugs_Fund.aspx
Market Place
Share 
